Abstract 1744P
Background
Patients with colon cancer from more deprived areas may face barriers to accessing timely, quality healthcare. These barriers may contribute to socioeconomic inequalities in survival. We examined differences in treatment and time to diagnosis and treatment between socioeconomic groups.
Methods
The English Cancer Registry identified a retrospective cohort of patients diagnosed with colon cancer in England between 2016-2017. Cancer Registry data were linked to Hospital Episode Statistics, Cancer Pathway, Systematic Anti-Cancer Dataset and Diagnostic Imaging Datasets. Lasso logistic regression identified predictors of colon cancer treatment. The secondary care diagnostic interval (SCDI) was used to calculate the time to diagnosis and treatment, analysed using quantile regression. All analyses were conducted using STATA. The study was registered on ClinicalTrials.gov (NCT05185388).
Results
A total of 35,248 patients were included in the analyses. Area deprivation was a significant predictor of receipt of surgery and chemotherapy. The adjusted odds of treatment were reduced for patients from the most deprived quintile: surgery (OR 0.78), chemotherapy in stage IV (OR 0.88), and chemotherapy in stage II-III (OR 0.79). The median SCDI was 20 days for patients from the most and least deprived areas. However, patients from the most deprived area had a significantly longer time to diagnosis after adjusting for other factors (median difference 0.73 days [95% CI 0.09-1.36]). Meanwhile, the median treatment interval was 55 and 57 days for patients from the least and most deprived areas, respectively. The treatment interval was significantly longer for patients from the most, compared with the least deprived areas after adjusting for important factors (median difference 2.29 days [95% CI 1.28-3.31]).
Conclusions
In this large cohort of patients with colon cancer in England, we demonstrated that patients from more deprived areas are less likely to receive surgery or chemotherapy and wait longer to commence treatment. Further research is needed to understand why and what evidence-based actions can reduce these inequalities in treatment and timeliness.
Clinical trial identification
NCT05185388.
Editorial acknowledgement
Legal entity responsible for the study
University of Hull.
Funding
Yorkshire Cancer Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23